Celltrion Inc. reported a dramatic turnaround in its second-quarter financial results, with net profit jumping nearly sixfold compared to the same period last year.
The South Korean biopharmaceutical company attributed the surge to robust sales of its biosimilar portfolio, marking a significant acceleration in commercial momentum for the firm.
Shares of Celltrion (068270.KS) climbed in Seoul trading following the announcement, reflecting investor enthusiasm for the record sales figures and improved bottom-line performance.
The stock’s upward movement underscores the market’s positive reception of the company’s operational strengthening and its ability to drive margin expansion through its core biosimilar products.
The results build on a broader trend of increasing foreign ownership in Celltrion during the first half of the year.
Overseas investors have been accumulating stakes, drawn by the company’s robust earnings trajectory and intensified investor relations efforts targeting international capital.